Detection of the Epstein-Barr virus in blood and bone marrow mononuclear cells of patients with aggressive B-cell non‑Hodgkin's lymphoma is not associated with prognosis
- Authors:
- Herlander Marques
- Raquel Catarino
- Nelson Domingues
- Eliane Barros
- Catarina Portela
- Maria Inês Almeida
- Sandra Costa
- Rui Manuel Reis
- Rui Medeiros
- Adhemar Longatto-Filho
View Affiliations
Affiliations: Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal, Molecular Oncology Group and Virology Laboratory, Portuguese Institute of Oncology, Porto, Portugal, Oncology‑Hematology Department, Institute of Oncology, Porto, Portugal, Department of Oncology, Hospital of Braga, Braga, Portugal
- Published online on: September 12, 2012 https://doi.org/10.3892/ol.2012.913
-
Pages:
1285-1289
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
The Epstein-Barr virus (EBV) is associated with a large spectrum of lymphoproliferative diseases. Traditional methods of EBV detection include the immunohistochemical identification of viral proteins and DNA probes to the viral genome in tumoral tissue. The present study explored the detection of the EBV genome, using the BALF5 gene, in the bone marrow or blood mononuclear cells of patients with diffuse large B-cell lymphomas (DLBCL) and related its presence to the clinical variables and risk factors. The results show that EBV detection in 21.5% of patients is not associated with age, gender, staging, B symptoms, international prognostic index scores or any analytical parameters, including lactate dehydrogenase (LDH) or β-2 microglobulin (B2M). The majority of patients were treated with R-CHOP‑like (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone or an equivalent combination) and some with CHOP-like chemotherapy. Response rates [complete response (CR) + partial response (PR)] were not significantly different between EBV-negative and -positive cases, with 93.2 and 88.9%, respectively. The survival rate was also similar in the two groups, with 5-year overall survival (OS) rates of 64.3 and 76.7%, respectively. However, when analyzing the treatment groups separately there was a trend in EBV-positive patients for a worse prognosis in patients treated with CHOP-like regimens that was not identified in patients treated with R-CHOP-like regimens. We conclude that EBV detection in the bone marrow and blood mononuclear cells of DLBC patients has the same frequency of EBV detection on tumoral lymphoma tissue but is not associated with the risk factors, response rate and survival in patients treated mainly with immunochemotherapy plus rituximab. These results also suggest that the addition of rituximab to chemotherapy improves the prognosis associated with EBV detection in DLBCL.
View References
|
1.
|
JI CohenEpstein-Barr virus infectionN Engl
J Med343481492200010.1056/NEJM20000817343070710944566
|
|
2.
|
DA Thorley-LawsonA GrossPersistence of the
Epstein-Barr virus and the origins of associated lymphomasN Engl J
Med35013281337200410.1056/NEJMra03201515044644
|
|
3.
|
G KellyA BellA RickinsonEpstein-Barr
virus-associated Burkitt lymphomagensis selects for downregulation
of the nuclear antigen EBNA2Nat
Med810981104200210.1038/nm75812219084
|
|
4.
|
PM BanksRA WarnkeMature T-cell and NK-cell
neoplasmsWHO Classification of Tumors: Pathology and Genetics of
Tumours of Hematopoetic and Lymphoid TissuesES JaffeNL HarrisH
SteinJW VardimanIARC PressLyon1892302001
|
|
5.
|
K KuzushimaH KimuraY HoshinoLongitudinal
dynamics of Epstein-Barr virus-specific cytotoxic T lymphocytes
during posttransplant lymphoproliferative disorderJ Infect
Dis182937940200010.1086/315791
|
|
6.
|
SJ Hamilton-DutoitM RaphaelJ AudouinIn
situ demonstration of Epstein-Barr virus small RNAs (EBER 1) in
acquired immunodeficiency syndrome-related lymphomas: correlation
with tumor morphology and primary siteBlood826196241993
|
|
7.
|
T OyamaK YamamotoN AsanoAge-related
EBV-associated B-cell lymphoproliferative disorders constitute a
distinct clinicopathologic group: a study of 96 patientsClin Cancer
Res1351245132200710.1158/1078-0432.CCR-06-282317785567
|
|
8.
|
RF AmbinderRB MannDetection and
characterization of Epstein-Barr virus in clinical specimensAm J
Pathol14523925219948053485
|
|
9.
|
R HassanLR WhiteCG StefanoffEpstein-Barr
(EBV) detection and typing by PCR: a contribution to diagnostic
screening of EBV-positive Burkitt’s lymphomaDiagn
Pathol11723200616893464
|
|
10.
|
D MoralesB BeltranFH De
MendozaEpstein-Barr virus as a prognostic factor in de novo nodal
diffuse large B-cell lymphomaLeuk
Lymphoma516672201010.3109/1042819090330801519860616
|
|
11.
|
S ParkJ LeeYH KoThe impact of Epstein-Barr
virus status on clinical outcome in diffuse large B-cell
lymphomaBlood110972978200710.1182/blood-2007-01-06776917400912
|
|
12.
|
S PaydasM ErginG SeydaogluPrognostic
significance of angiogenic/lymphangiogenic, anti-apoptotic,
inflammatory and viral factors in 88 cases with diffuse large B
cell lymphoma and review of the literatureLeuk
Res3341174126200910.1016/j.leukres.2009.02.01519286254
|
|
13.
|
T YoshinoS NakamuraY MatsunoEpstein-Barr
virus involvement is a preditive factor for the resistance to
chemoradiotherapy of gastric diffuse large B-cell lymphomaCancer
Sci97163166200610.1111/j.1349-7006.2006.00155.x16441428
|
|
14.
|
RJ TierneyN StevenLS YoungAB
RickinsonEpstein-Barr virus latency in blood mononuclear cells:
Analysis of viral gene transcription during primary infection and
in the carrier stateJ Virol68737473851994
|
|
15.
|
LL DeckerLD KlamanDA
Thorley-LawsonDetection of the latent form of Epstein-Barr virus
DNA in peripheral blood of healthy individualsJ
Virol703286329919968627812
|
|
16.
|
SH SwerdlowE CampoNE HarrisWHO
Classification of Tumours of Haematopoietic and Lymphoid Tissue4th
editionIARC PressLyon2008
|
|
17.
|
CA HeidJ StevensKJ LivakPM WilliamsReal
time quantitative PCRGenome
Res6986994199610.1101/gr.6.10.9868908518
|
|
18.
|
SE GibsonED HsiEpstein-Barr virus-positive
B-cell lymphoma of elderly at a United States tertiary medical
center: an uncommon aggressive lymphoma with a nongerminal center
B-cell phenotypeHum
Pathol40653661200910.1016/j.humpath.2008.10.007
|
|
19.
|
S HoellerA TzankovSA PileriEpstein-Barr
virus-positive diffuse large B cell lymphoma in elderly patients is
rare in Western populationsHum
Pathol41352357201010.1016/j.humpath.2009.07.02419913281
|
|
20.
|
N MounierJ BriereC GisselbrechtRituximab
plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to
chemotherapy in elderly patients with diffuse large B-cell lymphoma
(DLBCL)Blood10142794284200310.1182/blood-2002-11-344212576316
|
|
21.
|
N MilpiedB VasseurN ParquetHumanized
anti-CD20 monoclonal antibody (Rituximab) in post transplant
B-lymphoproliferative disorder: A retrospective analysis on 32
patientsAnn
Oncol11113116200010.1093/annonc/11.suppl_1.S11310707791
|
